816 related articles for article (PubMed ID: 32205092)
1. TH17 responses in cytokine storm of COVID-19: An emerging target of JAK2 inhibitor Fedratinib.
Wu D; Yang XO
J Microbiol Immunol Infect; 2020 Jun; 53(3):368-370. PubMed ID: 32205092
[TBL] [Abstract][Full Text] [Related]
2. Baricitinib, a drug with potential effect to prevent SARS-COV-2 from entering target cells and control cytokine storm induced by COVID-19.
Zhang X; Zhang Y; Qiao W; Zhang J; Qi Z
Int Immunopharmacol; 2020 Sep; 86():106749. PubMed ID: 32645632
[TBL] [Abstract][Full Text] [Related]
3. The potential of JAK/STAT pathway inhibition by ruxolitinib in the treatment of COVID-19.
Goker Bagca B; Biray Avci C
Cytokine Growth Factor Rev; 2020 Aug; 54():51-62. PubMed ID: 32636055
[TBL] [Abstract][Full Text] [Related]
4. Can Beta-2-Adrenergic Pathway Be a New Target to Combat SARS-CoV-2 Hyperinflammatory Syndrome?-Lessons Learned From Cancer.
Barbieri A; Robinson N; Palma G; Maurea N; Desiderio V; Botti G
Front Immunol; 2020; 11():588724. PubMed ID: 33117402
[TBL] [Abstract][Full Text] [Related]
5. The COVID-19 Cytokine Storm; What We Know So Far.
Ragab D; Salah Eldin H; Taeimah M; Khattab R; Salem R
Front Immunol; 2020; 11():1446. PubMed ID: 32612617
[TBL] [Abstract][Full Text] [Related]
6. Cytokine storm intervention in the early stages of COVID-19 pneumonia.
Sun X; Wang T; Cai D; Hu Z; Chen J; Liao H; Zhi L; Wei H; Zhang Z; Qiu Y; Wang J; Wang A
Cytokine Growth Factor Rev; 2020 Jun; 53():38-42. PubMed ID: 32360420
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of cytokine signaling by ruxolitinib and implications for COVID-19 treatment.
Yeleswaram S; Smith P; Burn T; Covington M; Juvekar A; Li Y; Squier P; Langmuir P
Clin Immunol; 2020 Sep; 218():108517. PubMed ID: 32585295
[TBL] [Abstract][Full Text] [Related]
8. Potential Treatments for COVID-19 Related Cytokine Storm - Beyond Corticosteroids.
Miao Y; Fan L; Li JY
Front Immunol; 2020; 11():1445. PubMed ID: 32612616
[No Abstract] [Full Text] [Related]
9. Should we unstress SARS-CoV-2 infected cells?
Csukasi F; Rico G; Becerra J; Duran I
Cytokine Growth Factor Rev; 2020 Aug; 54():3-5. PubMed ID: 32563554
[No Abstract] [Full Text] [Related]
10. COVID-19: Pathogenesis, cytokine storm and therapeutic potential of interferons.
Nile SH; Nile A; Qiu J; Li L; Jia X; Kai G
Cytokine Growth Factor Rev; 2020 Jun; 53():66-70. PubMed ID: 32418715
[TBL] [Abstract][Full Text] [Related]
11. Inflammation resolution: a dual-pronged approach to averting cytokine storms in COVID-19?
Panigrahy D; Gilligan MM; Huang S; Gartung A; Cortés-Puch I; Sime PJ; Phipps RP; Serhan CN; Hammock BD
Cancer Metastasis Rev; 2020 Jun; 39(2):337-340. PubMed ID: 32385712
[TBL] [Abstract][Full Text] [Related]
12. Acute inflammation and pathogenesis of SARS-CoV-2 infection: Cannabidiol as a potential anti-inflammatory treatment?
Costiniuk CT; Jenabian MA
Cytokine Growth Factor Rev; 2020 Jun; 53():63-65. PubMed ID: 32467020
[No Abstract] [Full Text] [Related]
13. The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammation.
La Rosée F; Bremer HC; Gehrke I; Kehr A; Hochhaus A; Birndt S; Fellhauer M; Henkes M; Kumle B; Russo SG; La Rosée P
Leukemia; 2020 Jul; 34(7):1805-1815. PubMed ID: 32518419
[TBL] [Abstract][Full Text] [Related]
14. SARS-CoV-2: An immunogenetics call to arms.
Clark B; Poulton K
Int J Immunogenet; 2020 Aug; 47(4):319-323. PubMed ID: 32654378
[TBL] [Abstract][Full Text] [Related]
15. Surviving the storm: Dealing with COVID-19.
Vandenbark AA; Meza-Romero R; Offner H
Cell Immunol; 2020 Aug; 354():104153. PubMed ID: 32563849
[No Abstract] [Full Text] [Related]
16. IL-6: Relevance for immunopathology of SARS-CoV-2.
Gubernatorova EO; Gorshkova EA; Polinova AI; Drutskaya MS
Cytokine Growth Factor Rev; 2020 Jun; 53():13-24. PubMed ID: 32475759
[TBL] [Abstract][Full Text] [Related]
17. Cytokines and COVID-19: friends or foes?
Rokni M; Hamblin MR; Rezaei N
Hum Vaccin Immunother; 2020 Oct; 16(10):2363-2365. PubMed ID: 32841579
[TBL] [Abstract][Full Text] [Related]
18. Tocilizumab administration in a refractory case of COVID-19.
Dastan F; Nadji SA; Saffaei A; Tabarsi P
Int J Antimicrob Agents; 2020 Aug; 56(2):106043. PubMed ID: 32502524
[No Abstract] [Full Text] [Related]
19. Gaining insights on immune responses to the novel coronavirus, COVID-19 and therapeutic challenges.
Hajivalili M; Hosseini M; Haji-Fatahaliha M
Life Sci; 2020 Sep; 257():118058. PubMed ID: 32653518
[TBL] [Abstract][Full Text] [Related]
20. SARS-CoV-2 infection-induced immune responses: Friends or foes?
Li K; Hao Z; Zhao X; Du J; Zhou Y
Scand J Immunol; 2020 Aug; 92(2):e12895. PubMed ID: 32445403
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
